The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them boomrx #peptides #fda #compoundingpharmacy #clinicalmedicine #patientaccess BoomRX Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law You may have seen headlines recently claiming peptides like MOTS C or BPC 157 are back let's talk about what this means. In 2023, the FDA placed 19 commonly used peptides into Category